Show simple item record

dc.contributor.authorZaidi, Sobia
dc.contributor.authorAmdur, Richard
dc.contributor.authorXiang, Xiyan
dc.contributor.authorYu, Herbert
dc.contributor.authorWong, Linda L
dc.contributor.authorRao, Shuyun
dc.contributor.authorHe, Aiwu R
dc.contributor.authorAmin, Karan
dc.contributor.authorZaheer, Daewa
dc.contributor.authorNarayan, Raj K
dc.contributor.authorSatapathy, Sanjaya K
dc.contributor.authorLatham, Patricia S
dc.contributor.authorShetty, Kirti
dc.contributor.authorGuha, Chandan
dc.contributor.authorGough, Nancy R
dc.contributor.authorMishra, Lopa
dc.date.accessioned2022-06-13T13:41:57Z
dc.date.available2022-06-13T13:41:57Z
dc.date.issued2022-06-06
dc.identifier.urihttp://hdl.handle.net/10713/19126
dc.description.abstractHepatocellular carcinoma (HCC) is the primary form of liver cancer and a major cause of cancer death worldwide. Early detection is key to effective treatment. Yet, early diagnosis is challenging, especially in patients with cirrhosis, who are at high risk of developing HCC. Dysfunction or loss of function of the transforming growth factor β (TGF-β) pathway is associated with HCC. Here, using quantitative immunohistochemistry analysis of samples from a multi-institutional repository, we evaluated if differences in TGF-β receptor abundance were present in tissue from patients with only cirrhosis compared with those with HCC in the context of cirrhosis. We determined that TGFBR2, not TGFBR1, was significantly reduced in HCC tissue compared with cirrhotic tissue. We developed an artificial intelligence (AI)-based process that correctly identified cirrhotic and HCC tissue and confirmed the significant reduction in TGFBR2 in HCC tissue compared with cirrhotic tissue. Thus, we propose that a reduction in TGFBR2 abundance represents a useful biomarker for detecting HCC in the context of cirrhosis and that incorporating this biomarker into an AI-based automated imaging pipeline could reduce variability in diagnosing HCC from biopsy tissue.en_US
dc.description.urihttps://doi.org/10.18632/genesandcancer.220en_US
dc.description.urihttp://www.ncbi.nlm.nih.gov/pmc/articles/pmc9170384/en_US
dc.language.isoenen_US
dc.publisherSAGE Publications Inc.en_US
dc.relation.ispartofGenes & Canceren_US
dc.subjectcirrhosisen_US
dc.subjectdiagnostic modelen_US
dc.subjectimmunohistochemistryen_US
dc.subjectliver canceren_US
dc.subjecttransforming growth factor betaen_US
dc.titleUsing quantitative immunohistochemistry in patients at high risk for hepatocellular cancer.en_US
dc.typeArticleen_US
dc.identifier.doi10.18632/genesandcancer.220
dc.identifier.pmid35677836
dc.source.journaltitleGenes & cancer
dc.source.volume13
dc.source.beginpage9
dc.source.endpage20
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record